These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25506251)

  • 1. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
    Lim T
    Hepat Med; 2014; 6():113-8. PubMed ID: 25506251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection.
    Lim TR; Tan BH; Mutimer DJ
    Int J Antimicrob Agents; 2014 Jan; 43(1):17-25. PubMed ID: 24183752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.
    Kamal SM
    Hepat Med; 2014; 6():61-77. PubMed ID: 25114601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.
    Ansaldi F; Orsi A; Sticchi L; Bruzzone B; Icardi G
    World J Gastroenterol; 2014 Aug; 20(29):9633-52. PubMed ID: 25110404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of metabolic factors with HCV infection: does it matter?
    Bugianesi E; Salamone F; Negro F
    J Hepatol; 2012; 56 Suppl 1():S56-65. PubMed ID: 22300466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.
    Elshimi E; Morad W; Mohamad NE
    J Sex Med; 2019 Mar; 16(3):402-409. PubMed ID: 30846113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection.
    Johnson LP; Sterling RK
    Biology (Basel); 2020 Apr; 9(4):. PubMed ID: 32344543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.
    Liu CJ; Jeng YM; Chen PJ; Lai MY; Yang HC; Huang WL; Kao JH; Chen DS
    Antivir Ther; 2005; 10(3):405-15. PubMed ID: 15918331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steatosis in hepatitis C virus infection. Response to anti-viral therapy.
    Szanto P; Grigorescu M; Dumitru I; Serban A
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):117-24. PubMed ID: 16802005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
    Coppola N; Pisaturo M; Zampino R; Macera M; Sagnelli C; Sagnelli E
    World J Gastroenterol; 2015 Oct; 21(38):10749-59. PubMed ID: 26478667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steatosis and hepatitis C.
    Modaresi Esfeh J; Ansari-Gilani K
    Gastroenterol Rep (Oxf); 2016 Feb; 4(1):24-9. PubMed ID: 26276502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating paediatric hepatitis C in the era of direct-acting antiviral agents.
    Alqahtani SA; Colombo MG
    Liver Int; 2021 Jun; 41(6):1189-1200. PubMed ID: 33533543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of steatosis in hepatitis C virus infection.
    Adinolfi LE; Restivo L; Marrone A
    Expert Rev Gastroenterol Hepatol; 2013 Mar; 7(3):205-13. PubMed ID: 23445230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection.
    Wong RJ; Gish RG
    Gastroenterol Hepatol (N Y); 2016 May; 12(5):293-9. PubMed ID: 27499712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.